SVB Leerink cuts Atea Pharmaceuticals (NASDAQ:AVIR) price target to $10.00

Atea Pharmaceuticals (NASDAQ:AVIR) had its price target reduced by stock analysts SVB Leerink from $11.00 to $10.00 in a report on Wednesday, Stock Target Advisor reports. The company currently has a “market performance” rating on the stock. SVB Leerink’s target price would suggest a potential upside of 55.76% from the company’s current price.

Several other brokerages also weighed in on AVIR. Zacks Investment Research downgraded Atea Pharmaceuticals from a “hold” rating to a “sell” rating in a report released Tuesday. JPMorgan Chase & Co. downgraded Atea Pharmaceuticals from an “overweight” rating to a “neutral” rating and cut its price target for the company from $61.00 to $16.00 in a Tuesday, October 19 report. Finally, Morgan Stanley downgraded Atea Pharmaceuticals from an “equal weight” rating to an “underweight” rating and reduced its target price for the company from $14.00 to $7.00 in a Thursday, Jan. 6, report. .

Shares of Atea Pharmaceuticals opened Wednesday at $6.42. The company has a fifty-day simple moving average of $7.69 and a 200-day simple moving average of $18.01. Atea Pharmaceuticals has a fifty-two week low of $6.02 and a fifty-two week high of $88.77.

Separately, director Polly A. Murphy purchased 12,000 shares of Atea Pharmaceuticals in a trade dated Monday, December 20. The shares were acquired at an average cost of $8.57 per share, with a total value of $102,840.00. The purchase was disclosed in a filing with the Securities & Exchange Commission, accessible via this hyperlink. Company insiders own 18.40% of the company’s shares.

(A d)

Hey, Tim Sykes here…and if you don’t know how to spot these classic trading patterns…then grab my free eBook now…Plus, I’ll be sharing my #1 rule for trading Penny Stocks.

A number of large investors have recently bought and sold shares of AVIR. Vanguard Group Inc. increased its position in Atea Pharmaceuticals by 309.8% during the second quarter. Vanguard Group Inc. now owns 4,536,163 shares of the company valued at $97,437,000 after purchasing an additional 3,429,258 shares during the period. Viking Global Investors LP acquired a new position in Atea Pharmaceuticals during the third quarter worth $58,027,000. Schroder Investment Management Group increased its position in Atea Pharmaceuticals by 9,984.5% during the fourth quarter. Schroder Investment Management Group now owns 1,541,106 shares of the company valued at $13,777,000 after purchasing an additional 1,525,824 shares during the period. State Street Corp increased its position in Atea Pharmaceuticals by 110.9% during the fourth quarter. State Street Corp now owns 2,325,453 shares of the company valued at $20,790,000 after purchasing an additional 1,222,601 shares during the period. Finally, Morgan Stanley increased its position in Atea Pharmaceuticals by 1,253.5% during the second quarter. Morgan Stanley now owns 789,348 shares of the company valued at $16,954,000 after purchasing an additional 731,027 shares during the period. 78.56% of the shares are currently held by hedge funds and other institutional investors.

Atea Pharmaceuticals Company Profile

Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, is focused on the discovery, development and commercialization of antiviral therapies for patients suffering from viral infections. Its lead product candidate is AT-527, a novel antiviral agent that is in Phase II clinical trials for the treatment of patients with COVID-19.

Featured articles

Stock Target Advisor Logo

This instant alert was powered by MarketBeat’s narrative science technology and financial data to provide readers with the fastest and most accurate reports. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send questions or comments about this story to [email protected]

Should you invest $1,000 in Atea Pharmaceuticals right now?

Before you consider Atea Pharmaceuticals, you’ll want to hear this.

MarketBeat tracks Wall Street’s top-rated, top-performing research analysts daily and the stocks they recommend to their clients. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the market takes off…and Atea Pharmaceuticals was not on the list.

While Atea Pharmaceuticals currently has a “Hold” rating among analysts, top-rated analysts believe these five stocks are better buys.

See the 5 actions here

Previous The price of a possible Kirk Cousins ​​extension may have been revealed
Next WWE Elimination Chamber PPV Prizes 2022: How much does it cost to watch the WWE event?